Long-term therapy of retinal vasculopathies with oral administration of high doses of O- (beta-hydroxyethyl) -rutoside
Agolini, G.; Cavallini, G.M.
La Clinica Terapeutica 120(2): 101-110
1987
ISSN/ISBN: 0009-9074 PMID: 2972438 Document Number: 4315
The results of an open clinical trial are presented. They were obtained in patients suffering from retinal vasculopathies of different etiologies. The patients were treated with O-(beta-hydroxyethyl)rutosides at high oral dosages. Seventy six patients (116 eyes) were studied. They were divided as follows: -ischaemic maculopathy: 24 patients (34 eyes) -patchy venous retinal thrombosis: 28 patients (38 eyes) -diabetic retinopathy: 16 patients (30 eyes) -haemorrhagic maculopathies in severe miopy: 8 patients (14 eyes). The drug was administered from 3 to 6 months at a dose of 2 g b.i.d. per os. The following parameters were examined: fundus, fluoroangiography and kinetic perimetry. Overall central vision was improved in 57% of the eyes, unchanged in 33% and worsened in 10%. From these results it may be concluded that the drug has been useful for the acceleration of the resorption of intra-retinal edema due to hypoxia induced by ischaemia. It was also valuable for the conservation and the improvement of central vision. At the dosage used, manifestions of intolerance were not observed.
Document emailed within 1 workday
